Trimethylamine-N-oxide is associated with cardiovascular mortality and vascular brain lesions in patients with atrial fibrillation
Marco Luciani,Daniel Müller,Chiara Vanetta,Thamonwan Diteepeng,Arnold von Eckardstein,Stefanie Aeschbacher,Nicolas Rodondi,Giorgio Moschovitis,Tobias Reichlin,Tim Sinnecker,Jens Wuerfel,Leo H Bonati,Seyed Soheil Saeedi Saravi,Patricia Chocano-Bedoya,Michael Coslovsky,Giovanni G Camici,Thomas F Lüscher,Michael Kuehne,Stefan Osswald,David Conen,Jürg Hans Beer,SWISS-AF Investigators,Chloé Auberson,Steffen Blum,Leo Bonati,Selinda Ceylan,Simone Evers- Doerpfeld,Ceylan Eken,Marc Girod,Elisa Hennings,Elena Herber,Vasco Iten,Philipp Krisai,Michael Kühne,Mirko Lischer,Christine Meyer-Zürn,Pascal Meyre,Andreas U Monsch,Christian Müller,Rebecca Paladini,Anne Springer,Christian Sticherling,Thomas Szucs,Gian Völlmin,Drahomir Aujesky,Urs Fischer,Juerg Fuhrer,Laurent Roten,Simon Jung,Heinrich Mattle,Luise Adam,Carole Elodie Aubert,Martin Feller,Axel Loewe,Elisavet Moutzouri,Claudio Schneider,Tanja Flückiger,Cindy Groen,Lukas Ehrsam,Sven Hellrigl,Alexandra Nuoffer,Damiana Rakovic,Nathalie Schwab,Rylana Wenger,Tu Hanh Zarrabi Saffari,Christopher Beynon,Roger Dillier,Michèle Deubelbeiss,Franz Eberli,Christine Franzini,Isabel Juchli,Claudia Liedtke,Samira Murugiah,Jacqueline Nadler,Thayze Obst,Jasmin Roth,Fiona Schlomowitsch,Xiaoye Schneider,Katrin Studerus,Noreen Tynan,Dominik Weishaupt,Andreas Müller,Simone Fontana,Corinne Friedli,Silke Kuest,Karin Scheuch,Denise Hischier,Nicole Bonetti,Alexandra Grau,Jonas Villinger,Eva Laube,Philipp Baumgartner,Mark Filipovic,Marcel Frick,Giulia Montrasio,Stefanie Leuenberger,Franziska Rutz,Jürg-Hans Beer,Angelo Auricchio,Adriana Anesini,Cristina Camporini,Giulio Conte,Maria Luce Caputo,Francois Regoli,Tiziano Moccetti,Roman Brenner,David Altmann,Michaela Gemperle,Peter Ammann,Mathieu Firmann,Sandrine Foucras,Martine Rime,Daniel Hayoz,Benjamin Berte,Virgina Justi,Frauke Kellner-Weldon,Brigitta Mehmann,Sonja Meier,Myriam Roth,Andrea Ruckli-Kaeppeli,Ian Russi,Kai Schmidt,Mabelle Young,Melanie Zbinden,Richard Kobza,Carlo Cereda,Alessandro Cianfoni,Maria Luisa De Perna,Jane Frangi-Kultalahti,Patrizia Assunta Mayer Melchiorre,Anica Pin,Tatiana Terrot,Luisa Vicari,Georg Ehret,Hervé Gallet,Elise Guillermet,Francois Lazeyras,Karl-Olof Lovblad,Patrick Perret,Philippe Tavel,Cheryl Teres,Dipen Shah,Nathalie Lauriers,Marie Méan,Sandrine Salzmann,Jürg Schläpfer,Alessandra Pia Porretta,Andrea Grêt,Jan Novak,Sandra Vitelli,Frank-Peter Stephan,Augusto Gallino,Marcello Di Valentino,Helena Aebersold,Fabienne Foster,Matthias Schwenkglenks,Jens Würfel,Anna Altermatt,Michael Amann,Marco Düring,Petra Huber,Esther Ruberte,Vanessa Zuber,Pascal Benkert,Gilles Dutilh,Milica Markovic,Pia Neuschwander,Patrick Simon,Ramun Schmid
DOI: https://doi.org/10.1136/heartjnl-2022-321300
IF: 5.7
2023-02-14
Heart
Abstract:Objective: Trimethylamine-N-oxide (TMAO) is a metabolite derived from the microbial processing of dietary phosphatidylcholine and carnitine and the subsequent hepatic oxidation. Due to its prothrombotic and inflammatory mechanisms, we aimed to assess its role in the prediction of adverse events in a susceptible population, namely patients with atrial fibrillation. Methods: Baseline TMAO plasma levels were measured by liquid chromatography-tandem mass spectrometry in 2379 subjects from the ongoing Swiss Atrial Fibrillation cohort. 1722 underwent brain MRI at baseline. Participants were prospectively followed for 4 years (Q1-Q3: 3.0-5.0) and stratified into baseline TMAO tertiles. Cox proportional hazards and linear and logistic mixed effect models were employed adjusting for risk factors. Results: Subjects in the highest TMAO tertile were older (75.4±8.1 vs 70.6±8.5 years, p<0.01), had poorer renal function (median glomerular filtration rate: 49.0 mL/min/1.73 m2 (35.6-62.5) vs 67.3 mL/min/1.73 m2 (57.8-78.9), p<0.01), were more likely to have diabetes (26.9% vs 9.1%, p<0.01) and had a higher prevalence of heart failure (37.9% vs 15.8%, p<0.01) compared with patients in the lowest tertile. Oral anticoagulants were taken by 89.1%, 94.0% and 88.2% of participants, respectively (from high to low tertiles). Cox models, adjusting for baseline covariates, showed increased total mortality (HR 1.65, 95% CI 1.17 to 2.32, p<0.01) as well as cardiovascular mortality (HR 1.86, 95% CI 1.21 to 2.88, p<0.01) in the highest compared with the lowest tertile. When present, subjects in the highest tertile had more voluminous, large, non-cortical and cortical infarcts on MRI (log-transformed volumes; exponentiated estimate 1.89, 95% CI 1.11 to 3.21, p=0.02) and a higher chance of small non-cortical infarcts (OR 1.61, 95% CI 1.16 to 2.22, p<0.01). Conclusions: High levels of TMAO are associated with increased risk of cardiovascular mortality and cerebral infarction in patients with atrial fibrillation. Trial registration number: NCT02105844.